Dr. Kieran received his PhD from the University of Alberta and MD from the University of Calgary in Canada. He then completed a post-doctoral fellowship in molecular biology at the Pasteur Institute in Paris France followed by his residency in pediatrics at McGill University in Montreal, Canada. Dr Kieran then completed a fellowship in pediatric hematology and oncology at the Children’s Hospital Boston. This was followed by a second research fellowship in cellular signal transduction, also at Children’s Hospital Boston. In 1997, Dr Kieran was named the Director of Pediatric Medical Neuro-Oncology at the Dana-Farber Cancer Institute and Children’s Hospital and is currently an Associate Professor of Pediatrics at Harvard Medical School. With Dr Kieran’s research and clinical training, he started a translational research lab in the Vascular Biology Program under the Chairmanship of the late Dr Judah Folkman in 1998. Another pediatric oncologist by the name of Dr Tim Browder, along with Dr Folkman, had proposed in 1991 that currently available drugs, including traditional chemotherapy agents, if given in low regular doses, could attack the blood supply of tumor, a process called anti-angiogenesis. In 2000, after successfully demonstrating this for the first time in animal models of disease, this process was renamed metronomic therapy. Working with Drs Browder and Folkman, the first formal clinical trial of this approach was undertaken and demonstrated excellent tolerability and success. Dr Kieran’s laboratory has continued to research other compounds with metronomic properties and has completed 4 prospective clinical trials in hundreds of patients using this approach. Dr Kieran has received numerous awards, is actively involved in a number of medical and scientific journals, and has traveled around the world lecturing on metronomic chemotherapy for children with cancer. He has a number of grants supporting his research and clinical trials and has published extensively in this area. In addition, Dr Kieran is co-chair of the malignant glioma program of the Children’s Oncology Group (COG) as well as Principle Investigator of the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) in Boston, an international organization for testing novel therapies in children with cancer.